Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
- Conditions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT00083187
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇫🇷Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
🇬🇧King's College Hospital, London, England, United Kingdom
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 5
- Registration Number
- NCT00004933
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00019474
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Radiation Therapy in Treating Patients With Glioblastoma
- Conditions
- First Posted Date
- 2004-04-05
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT00019058
- Locations
- 🇺🇸
Radiation Oncology Branch, Bethesda, Maryland, United States
Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Ottawa Regional Cancer Centre
- Target Recruit Count
- 30
- Registration Number
- NCT00002887
- Locations
- 🇨🇦
Ottawa Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 744
- Registration Number
- NCT00002868
- Locations
- 🇬🇧
Royal Infirmary, Glasgow, Scotland, United Kingdom
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Riverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 800
- Registration Number
- NCT00002869
- Locations
- 🇬🇧
Western General Hospital, Edinburgh, Scotland, United Kingdom
Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
- Conditions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Registration Number
- NCT00002940
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
- Conditions
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004094
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Monroe Medical Associates, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
- Conditions
- First Posted Date
- 2003-03-13
- Last Posted Date
- 2019-11-22
- Target Recruit Count
- 39
- Registration Number
- NCT00056433
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.